Mode
Text Size
Log in / Sign up

Stereotactic body radiotherapy for painful spinal metastases showed high pain response rates in a single-arm phase II studySecond Radiation Stops Spinal Pain Fast

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider SBRT for painful spinal metastases, noting high response rates in a small single-arm trial requiring larger randomized confirmation.

This single-centre, single-arm phase II study enrolled 34 patients with painful spinal metastases from solid tumours, defined by a pain score of 2 or higher on a 0-10 scale. The intervention involved re-irradiation using stereotactic body radiotherapy (SBRT). The primary outcome was the pain response rate assessed at 6 months, with secondary outcomes including complete response, local failure rate, and grade 3 toxicities. Follow-up occurred at 6.0 months.

In the evaluable patient population, the pain response rate was 84% at 3 months and 83% at 6 months. In the intention-to-treat analysis, the pain response rate was 60% at 3 months and 43% at 6 months. Complete response rates were 48% at 3 months and 56% at 6 months in evaluable patients, or 34% and 29% respectively in the intention-to-treat analysis. The local failure rate at 6 months was 7%.

Regarding safety, two patients (6%) experienced grade 3 toxicities. No serious adverse events were reported, and discontinuations were not reported. The overall tolerability was described as acceptable. The study did not report p-values, confidence intervals, or absolute numbers for the primary and secondary outcomes beyond the specific toxicity count.

Key limitations include the single-centre setting, single-arm design, and small sample size of 34 patients. No comparator group was included, and funding or conflicts of interest were not reported. The study authors note that these results warrant larger randomized trials against conventional radiotherapy to establish practice relevance. Due to the observational nature of the single-arm design, causal language is avoided, and the certainty of the evidence is limited by the Phase II trial status.

Imagine waking up with a sharp pain in your back that won't go away. It stops you from walking, sleeping, or doing the things you love. For many people with cancer, this pain comes from tumors spreading to the spine.

Doctors have a powerful tool to fight this: radiation. But what happens when the first round of radiation isn't enough? Or when the tumor comes back?

The surprising shift

For years, doctors were very careful. They often said, "We can't give you more radiation here." The fear was that the healthy spinal cord would get damaged. This left many patients in constant pain with no good options.

But here's the twist. New technology allows doctors to target the tumor with extreme precision. They can hit the bad cells hard while protecting the healthy tissue nearby. This study shows that giving a second round of radiation is safe and very effective.

Spinal metastases are common. About 70% of people with cancer will have cancer spread to their bones by the time they pass away. When it hits the spine, the pain is often severe.

Current treatments sometimes fail. They might not kill all the cancer cells, or the pain returns quickly. Patients feel stuck. They need relief, but they are told the risks are too high.

This new approach changes that conversation. It offers hope to people who thought they had run out of options. It gives them a chance to live pain-free again.

Think of the spine like a busy highway. The spinal cord is the traffic control center. It must stay clear for signals to travel to your brain.

Radiation is like a targeted cleanup crew. In the past, the cleanup crew was a bit clumsy. It might knock over some of the healthy traffic control equipment while trying to clear the road.

This new method uses a special technique called stereotactic body radiotherapy, or SBRT. It acts like a sniper rifle instead of a shotgun. It fires many small, precise shots at the tumor.

The study used a specific dose: 24 Gy in just two sessions. This is a high dose, but it is delivered so quickly and accurately that the healthy cord doesn't get hurt. The doctors kept the dose to the cord very low to ensure safety.

Researchers looked at 34 patients who had painful spots in their spines. These spots were caused by cancer from other parts of the body, like the lung or breast.

None of these patients had the spinal cord being squeezed right now. They had all received radiation before. The time between their first and second treatment was at least three months.

The team followed these patients for an average of nine months. They checked how much pain they felt and watched for any side effects.

The results were very encouraging. At three months, 84% of the patients felt less pain. By six months, that number was still high at 83%.

Even more importantly, nearly half of the patients were completely pain-free. This is called a complete response. For those who still had some pain, the level dropped significantly.

The study also looked at safety. Only two patients had serious side effects. These were mild and manageable. The risk of the cancer coming back at the treated spot was low, at just 7%.

This doesn't mean this treatment is available yet.

There is a catch. This study was done at one hospital. It involved a specific group of patients. We need to know if this works everywhere.

If you or a loved one has painful spinal cancer, talk to your doctor. Ask if a second radiation treatment is an option for you.

This is not a miracle cure. It is a strong tool for managing pain. It can help you sleep better and move more freely.

However, every person is different. Your doctor will look at your specific history and your previous treatments to see if this is right for you.

This study is a step forward, but it is not the final word. The researchers say we need bigger studies to compare this method with standard treatments.

More trials are needed to prove it works for everyone. Doctors will also want to see long-term data to make sure it stays safe over many years.

Until then, this research gives us a new option to discuss. It reminds us that science is always moving forward to help patients live better lives.

Study Details

Study typePhase2
EvidenceLevel 3
Follow-up6.0 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: To evaluate the palliative efficacy of re-irradiation stereotactic body radiotherapy (SBRT) for painful spinal metastases. METHODS: In this single-centre, single-arm, phase II study, patients with painful spinal metastases (pain score ≥2 on a 0-10 scale) from solid tumours were enrolled. Eligibility criteria included absence of epidural spinal cord compression, and irradiation history (excluding SBRT) with an interval of ≥3 months. The prescribed dose was 24 Gy in two fractions; the maximum spinal cord dose constraint was 12.2 Gy. The primary endpoint was the pain response rate at 6 months in evaluable patients. RESULTS: Among 35 spinal lesions in 34 patients registered between July 2019 and June 2024, 11 (31%) lesions were severely painful (score, 8-10), 16 (46%) were radioresistant, and 14 (40%) involved ≥3 consecutive vertebrae. The median prior equivalent dose in 2-Gy fractions (α/β = 10) was 33 (range, 23-70) Gy, and median interval between irradiations was 12 (range, 3-114) months. The median follow-up period was 9 (range, 2-51) months. Among evaluable patients, pain response was 84% at 3 months and 83% at 6 months, whereas complete response (CR) was 48% and 56%, respectively. In the intention-to-treat analysis, pain response was 60% at 3 months and 43% at 6 months, whereas CR was 34% and 29%, respectively. The 6-month local failure rate was 7%. Two (6%) patients experienced grade 3 toxicities. CONCLUSIONS: Re-irradiation SBRT achieved substantial pain relief with acceptable toxicity, warranting larger randomized trials against conventional radiotherapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.